Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Xenoscience

Neither a doctor nor a teaching hospital

Research payments

$950,422

185 payments

Through program year 2025, Xenoscience is reported as receiving $950,422 in research payments, across 185 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $143,812 4
2024 Research $30,892 7
2023 Research $24,338 8
2022 Research $95,753 13
2021 Research $144,167 43
2020 Research $217,980 66
2019 Research $293,480 44

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $288,391 65 payments
  2. Eisai Inc. $220,693 82 payments
  3. E.R. Squibb & Sons, L.L.C. $145,910 3 payments
  4. Biogen, Inc. $100,146 2 payments
  5. AbbVie, Inc. $77,492 8 payments
  6. SK Life Science, Inc. $46,530 11 payments
  7. Ucb SA $29,958 4 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $23,143 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $7,687 5 payments
  10. Celgene Corporation $7,428 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease $210,472 81 payments
  2. A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) $143,104 2 payments
  3. A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the Conquer Study $76,927 2 payments
  4. Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease $68,938 1 payment
  5. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Ly3451838 in Adults With Treatment-Resistant Migraine $63,834 8 payments
  6. A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinsons Disease Patients $60,137 5 payments
  7. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy $31,208 1 payment
  8. Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $30,866 4 payments
  9. A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the Rebuild Study $22,470 6 payments
  10. 59566 $21,014 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record